NCT04278222View on ClinicalTrials.gov

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions

Gastric CancerImmunotherapyAnlotinibToripalimab

Interventions

DRUG

Anlotinib Plus Toripalimab

Anlotinib 12mg oral administration daily d1-d14, q3w; Toripalimab 240mg iv drop d1, q3w

Trial Locations (1)

Unknown

RECRUITING

Department of Medical Oncology, Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Changzheng Hospital

OTHER

NCT04278222 - Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) | Biotech Hunter | Biotech Hunter